35 results about "Anti viral response" patented technology

The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.

The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.

Oligonucleotides bearing free, uncapped 5′ phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1β production. Bacterial RNA also induces type I IFN production. 5′ phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and / or IL-18 and / or IL-1β production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5′ triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and / or IL-18 and / or IL-1β production, in a target cell-specific manner.

The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer.

The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer.

The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.

The present invention relates to therapeutic use of Myxoma virus. Myxoma virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.

The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R.

The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.

The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.

This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.

The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.

The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.

An expression vector is constructed by transferring recombinant tomato mosaic virus (ToMV) cDNA, in which a coat protein gene of ToMV having a suppressor against a virus resistant reaction has been substituted by a GFP gene, into the downstream of a promoter capable of inducing steroid hormone-dependent transcription. In a transformed tobacco BY-2 cell obtained by transferring the above expression vector into a tobacco BY-2 cells, steroid hormone-dependent transcription is induced, thereby enabling the amplification of mRNA of the GFP gene and induction of the expression of GFP.

This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences dendritic cell (DC) response(s), for example, dendritic cell maturation, dendritic cell antiviral response(s) and / or dendritic cell inflammatory response(s), as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences dendritic cell response(s) in a variety of therapeutic and / or diagnostic indications.

Disclosed herein are compounds, pharmaceutical compositions, and related methods for the treatment of viral infection, including RNA viral infection in subjects. The compounds, pharmaceutical compositions, and methods can modulate the innate immune antiviral response in vertebrate cells, including activating the RIG-I pathway.

This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.

The invention discloses an application of MVP used as an antiviral drug target. The invention verifies that a high expression of MVP can be detected in the hepatic tissue, the blood serum and the human peripheral mononuclear cells separated from the blood of a hepatitis C patient; meanwhile, as shown in an in vitro experiment, the mRNA and protein expression levels of MVP in the cell increase after the hepatitis C virus is infected with Huh7 and Huh7.5.1 cells, and VSV, IAV, and EV71 can induce the MVP expression to inhibit the virus copy so as to realize an antiviral function. As shown in a further mechanism research, the MVP expression increases after the virus stimulates the organism, and the MVP induces the generation of I-type interferon to inhibit the virus copy so as to realize theantiviral function. The application of MVP used as antiviral drug target provided in the invention can be used as a novel drug target to develop medicine for treating hepatitis caused by HCV and diseases caused by other viruses.

The invention discloses a novel coronavirus subprotein nano vaccine and a preparation method and application thereof. The nano vaccine comprises: an organic compound self-assembled by polylactic acid, a porphyrin or a porphyrin derivative and a Co2+ ion conjugate; a novel coronavirus antigen protein; a vaccine adjuvant and lipid. According to the invention, a core of the synthesized organic compound is coated with the adjuvant, and the surface of the synthesized organic compound is efficiently loaded with the novel coronavirus antigen protein, so that a nano vaccine system for co-delivery of the novel coronavirus antigen protein and the vaccine adjuvant is implemented, and not only the immunogenicity of a novel coronavirus recombinant subprotein can be played to the greatest extent, but also the distribution condition of the nano vaccine in a living body can be traced through fluorescent molecules. In addition, the nano vaccine provided by the invention is also connected with polypeptide capable of specifically targeting antigen presenting cells, so that the nano vaccine is promoted to be massively ingested by DC cells, and the antiviral reaction is promoted. Meanwhile, the preparation method of the nano vaccine is simple and efficient, and a brand new way is provided for effective prevention of novel coronavirus infection.

The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases.

Modified viral genomes are able to reduce induction of inflammatory and immune anti-viral responses. This manifests itself in reduced NF-kB activity, increased viral transduction rates, and increased expression of transgenes. Viral genomes are modified by incorporating one or more oligonucleotide sequences which are able to bind to TLR9 but not induce activation of it. The oligonucleotide sequences may be synthetic, bacterial, human, or from any other source.

The invention provides an anti-African swine fever virus fusion protein as well as a preparation method and application thereof, and belongs to the technical field of gene engineering, the anti-African swine fever virus fusion protein comprises a structural protective peptide DNBLK1 and an active protein, and the structural protective peptide DNBLK1 and the active protein are connected through a connecting peptide; wherein the active protein is porcine autoimmune regulator protein INF-gamma or antiviral polypeptide IFN-alpha; wherein the porcine autoimmune modulator protein can activate an immune system in a pig body at the first time of virus infection and activate an antiviral reaction; the antiviral polypeptide directly acts on the virus to inhibit the replication of the virus in vivo and destroy the virus structure; and the two components have a synergistic effect to realize prevention and treatment of African swine fever. The drug for preventing and / or treating African swine feverprovided by the invention has the advantages of broad-spectrum disease resistance, small residue, no pollution, no drug resistance, no drug residue and the like, is used in the early stage of virus infection, and has a remarkable prevention and control effect.

The invention specifically relates to a drug capable of inhibiting the Newcastle disease virus, belonging to the field of marine biotechnology. the drug capable of inhibiting the Newcastle disease virus is low-molecular-weight beta-chitosan. The low-molecular-weight beta-chitosan can substantially improve expression of immune factors like IL-2, TLR-7, IFN-beta and TNF-alpha so as to excite antiviral response of an immune system and improve immunity of poultry, so attack and diffusion of the Newcastle disease virus are effectively inhibited. Research on the inhibition effects of the beta-chitosan on the Newcastle disease virus provides effective bases and possible drug research and development directions for prevention and treatment of other viral diseases.

The invention relates to a goose-derived mitochondrial anti-virus signal protein and its application, in particular to a goose-derived mitochondrial anti-virus signal protein with anti-virus and immune activation functions and its application. The signal protein includes an active region, a proline Any one or a combination of at least two of the enrichment region, domain A, domain B or transmembrane region. The goose-derived mitochondrial antiviral signal protein can induce a high level of innate antiviral response in primary goose embryo fibroblasts, and can inhibit the early replication of Newcastle disease virus.

The invention discloses an application of MVP used as an antiviral drug target. The invention verifies that a high expression of MVP can be detected in the hepatic tissue, the blood serum and the human peripheral mononuclear cells separated from the blood of a hepatitis C patient; meanwhile, as shown in an in vitro experiment, the mRNA and protein expression levels of MVP in the cell increase after the hepatitis C virus is infected with Huh7 and Huh7.5.1 cells, and VSV, IAV, and EV71 can induce the MVP expression to inhibit the virus copy so as to realize an antiviral function. As shown in a further mechanism research, the MVP expression increases after the virus stimulates the organism, and the MVP induces the generation of I-type interferon to inhibit the virus copy so as to realize the antiviral function. The application of MVP used as antiviral drug target provided in the invention can be used as a novel drug target to develop medicine for treating hepatitis caused by HCV and diseases caused by other viruses.

The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases.

The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.